细胞减少
骨髓增生异常综合症
医学
前瞻性队列研究
人口
重症监护医学
临床试验
肿瘤科
危险分层
内科学
临床意义
生物信息学
髓样
血液恶性肿瘤
儿科
髓性白血病
血液肿瘤
临床终点
作者
Zhuoer Xie,Zena Komrokji,Michael Christopher Otterstatter,Ling Zhang,Lynn C. Moscinski,Najla Al‐Ali,David Andrew Sallman,Jeffrey E. Lancet,Gregory Alan Abel,Robert Coleman Lindsley,Rafael L. Bejar,Matthew J. Walter,Amy Elizabeth Dezern,Mikkael Aaron Sekeres,Rami S. Komrokji,Nancy Gillis,Eric Padron
出处
期刊:Blood
[Elsevier BV]
日期:2026-07-29
卷期号:148 (20): 2528-2539
被引量:1
标识
DOI:10.1182/blood.2026033085
摘要
ABSTRACT: Clonal cytopenia of undetermined significance (CCUS) is defined by unexplained cytopenias with myeloid-associated somatic mutations not meeting the diagnostic criteria for myelodysplastic syndromes/neoplasms (MDS), yet it carries a highly risk-stratified probability of progression to myeloid neoplasms. The clinical distinction between CCUS and lower-risk MDS (LR-MDS) is challenging because current criteria rely heavily on semiquantitative morphologic thresholds, despite substantial clinical and molecular overlap. In this prospective study of 409 patients with CCUS and 241 with LR-MDS, we applied harmonized diagnostic and progression criteria, rigorous centralized pathology review, and uniform genomic profiling to compare clinical, molecular, and outcome data. Risk stratification was performed using 2 independent models: the clonal hematopoiesis risk score (CHRS) and the clonal cytopenia risk score (CCRS). Patients with high-risk CCUS, as defined by CHRS or CCRS, exhibited clinical features and event rates comparable to those with LR-MDS. In contrast, patients with low- or intermediate-risk CCUS had markedly improved outcomes, supporting conservative management. These findings underscore that CHRS and CCRS are clinically informative tools that extend beyond morphology-based classification and enable a risk-adapted approach to the management of CCUS. Importantly, a subset of patients with high-risk CCUS demonstrated substantial clinical and genomic convergence with LR-MDS, supporting their consideration for enrollment in prospective clinical trials designed for LR-MDS. These observations highlight the need for further study of risk-adapted therapeutic approaches in this population and underscore the importance of prospective clinical evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI